v phenylephrine hcl 0 04 chlorpheniramine maleate 0 056 tannic acid usp 0 12 magnesium aluminum silicate nf 0 80 citric acid 0 44 sodium saccharin 0 30 sucrose nf 10 00 glycerin usp 7 50 sodium citrate dihydrate usp 1 00 methylparaben 0 20 sodium benzoate nf 0 10 xanthan gum 0 52 grape flavor 0 20 fd amp c blue 1 0 002 fd amp c red 40 0 005 purified water usp n a raw material w v phenylephrine hcl 0 04 chlorpheniramine maleate 0 056 tannic acid usp 0 12 neusilin u00ae nf 0 80 citric acid 0 44 sodium saccharin 0 30 sucrose nf 10 00 glycerin usp 7 50 sodium citrate dihydrate usp 1 00 methylparaben 0 20 sodium benzoate nf 0 10 xanthan gum 0 52 grape flavor 0 20 fd amp c blue 1 0 002 fd amp c red 40 0 005 purified water usp n a the assay results for chlorpheniramine maleate and phenylephrine hcl in samples stored at 25 u00b0 c and 60 relative humidity rh are shown in table 1 after 12 months composition a with mas showed a loss of phenylephrine at 11 9 while composition b with neusilin u00ae showed no decrease nc in phenylephrine with regard to chlorpheniramine composition a with mas showed an increase of chlorpheniramine at 4 2 while composition b with neusilin u00ae showed no increase or decrease in chlorpheniramine the increase in chlorpheniramine remains within the acceptable range of 90 0 110 0 label claim lc a comparative study was carried out to evaluate mas versus neusilin u00ae with regard to the stability of diphenhydramine hcl and phenylephrine hcl in a chewable tablet formulation containing each active ingredient as a tannate salt complex prepared according to u s 2003 0077321.